A Study to Assess the Pharmacokinetic Comparability of Guselkumab (CNTO1959) When Delivered by 2 Different Devices and as 2 Formulations in Healthy Participants
Part of paid clinical trials in Tempe, Arizona.
- Sponsor
- Janssen Research & Development, LLC
- Study ID
- NCT01866007
- Phase
- PHASE1
- Status
- Completed
Conditions
- Healthy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 55 Years
- Healthy Volunteers
- Accepted
Interventions
- Guselkumab (lyophilized formulation) — DRUGParticipants will receive a single SC injection of 100 mg guselkumab prepared from lyophilized formulation.
- Guselkumab (liquid formulation with PFS-U) — DRUGParticipants will receive a single SC injection of 100 mg guselkumab, liquid formulation with PFS-U.
- Guselkumab (liquid formulation with PFS FID) — DRUGParticipants will receive a single SC injection of 100 mg guselkumab, liquid formulation with PFS FID.
- Guselkumab (liquid formulation) — DRUGParticipants will receive a single IV infusion of 100 mg guselkumab prepared from liquid formulation.
Study Details
The purpose of this study is to evaluate the pharmacokinetic (what the body does to the medication) comparability of guselkumab in lyophilized and liquid formulations. Also to evaluate pharmacokinetic comparability of liquid formulation of guselkumab when delivered as prefilled syringe with UltraSafe Passive Delivery System \[PFS-U\] or with a prefilled syringe facilitated injection device \[PFS FID\]) following a single subcutaneous (SC) administration of 100 mg guselkumab in healthy participants.
Key Dates
- Start date
- May 9, 2013
- Status verified
- Jan 2020
- Primary completion
- Sep 20, 2013
- Completion
- Oct 9, 2013
Study Design
- Enrollment
- 141 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Group 140 participants will receive a single subcutaneous (SC) injection of 100 mg guselkumab prepared from lyophilized formulation.
- Experimental: Group 240 participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with UltraSafe Passive Delivery System (PFS-U).
- Experimental: Group 340 participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with a prefilled syringe facilitated injection device (PFS FID).
- Experimental: Group 420 participants will receive a single intravenous (IV) infusion of 100 mg guselkumab prepared from liquid formulation.
Primary Outcome Measure
Maximum observed serum concentration (Cmax) of guselkumab [ Time Frame: Day 1 through Week 12 ]
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| - | Tempe | Arizona | - | - |
| - | Lincoln | Nebraska | - | - |
| - | Neptune City | New Jersey | - | - |
Related Studies
- A Study to Evaluate the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut DysbiosisRecruiting · Mayo Clinic · Scottsdale, Arizona
- A Study of Neurodegeneration and Neuronal Fluctuations in Lewy Body Disease and Alzheimer's DiseaseRecruiting · Mayo Clinic · Scottsdale, Arizona
- Brain Criticality, Oculomotor Control, and Cognitive EffortRecruiting · Rutgers, The State University of New Jersey · Piscataway, New Jersey
- A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).PHASE1 · Recruiting · Merck Sharp & Dohme LLC · Glendale, California